Phosphopantetheine compounds alone or in combination with HMG-CoA reductase inhibitors for lowering serum cholesterol and serum triglicerides

ABSTRACT

The invention relates to the use of phosphopantetheine compounds alone and in combination with 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. Preferred medical uses relate to the treatment or prevention of dyslipidemia.

RELATED APPLICATIONS

This application is a U.S. National Phase application, filed under 35U.S.C. § 371(c), of International Application No. PCT/EP2015/081184,filed Dec. 23, 2015, which claims the benefit of and priority toSlovenian Patent Application No. P-201400452, filed Dec. 23, 2014. Theentire contents of each of these Applications are incorporated herein byreference in their entireties.

FIELD OF THE INVENTION

The present invention relates to the use of phosphopantetheine compoundsfor treatment or prevention of dyslipidemia. This invention also relatesto combinations of 3-hydroxy-3-methylglutaryl-coenzyme A reductaseinhibitors and phosphopantetheine compounds and medical uses thereof.

BACKGROUND OF THE INVENTION

HMG-CoA reductase or 3-hydroxy-3-methyl-glutaryl-CoA reductase is therate-controlling enzyme of the mevalonate pathway, the metabolic pathwaythat produces cholesterol and other isoprenoids. Competitive inhibitorsof HMG-CoA reductase increase the expression of low density lipoprotein(LDL) receptors in the liver, which in turn increases the catabolism ofplasma LDL and decreases the plasma concentration of cholesterol, animportant determinant of atherosclerosis. Therefore, HMG-CoA reductasehas therefore been a target for pharmaceutical intervention, resultingin a group of widely available cholesterol-lowering drugs knowncollectively as the statins. These drugs include for example oflovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin,cerivastatin, mevastatin and rosuvastatin. However, despite increasinguse of statins, even in optimal doses to achieve target LDL-cholesterolreduction, considerable residual risk remains. Such risk resides inelevated levels of triglycerides (TG), and subnormal levels ofartheroprotective high-density lipoprotein cholesterol (HDL-cholesterol)[Lai et al. Lipids in Health and Disease, 2014, 13:1].

The metabolic cofactor coenzyme A (CoA) is an acyl group carrierinvolved in the oxidative catabolism of fatty acids as well as intransferring fatty acids from the cytoplasm to mitochondria. CoA isessential for over 100 metabolic reactions, and it has been estimatedthat CoA is an obligatory cofactor for 4% of known enzymatic reactions.Eukaryotic cells are believed to obtain this essential cofactor via anintracellular de novo biosynthetic route. This canonical pathway startswith the uptake of extracellular vitamin B5, which is converted via fiveconserved enzymatic reactions into intracellular Coenzyme A. Theseenzymes are, in order, pantothenate kinase, phosphopantothenoyl cysteinesynthetase, phospho-N-pantothenoylcysteine decarboxylase,phosphopantetheine adenylyltransferase and dephospho-CoA kinase.

Administering patients with moderate dyslipidemia with CoA was shown toeffectively reduce plasma triglyceride levels [Chen et al., J ClinEnocrinol Metab, 2013, 98: E275-E278]. It has been described thatcombinations of statins and Coenzyme A in patients withhypercholesterolemia and hypertriglyceridemia, improved triglyceridelevels and other lipoprotein parameters to a greater extent than statinalone [Lai et al. Lipids in Health and Disease, 2014, 13:1]. Similarcombinations have also been shown effective in reducing plasma lipidlevels rabbits and rats [Na et al., Academic Journal of Second MilitaryMedical University, 2004, 25:255-257]. However, due to its complexchemical structure Coenzyme A is not readily available in industrialamounts through chemical synthesis. Coenzyme A from microbial sources,can be obtained, however yields are relatively low and isolation complex[Nishimura et al., Appl Microbiol. 1974, 28:117-23; Shimizu et al., ApplEnviron Microbiol. 1984, 48:1118-22], therefore coenzyme A is not widelyavailable in pure form.

SUMMARY OF THE INVENTION

Against this background, it is an object of the invention to providenovel pharmaceutical compositions useful for treating dyslipidemia, suchas hyperlipidemia, hypercholesterolemia, hyperlipoproteinemia andhypertriglyceridemia and particularly combined hyperlipidemia. It isanother object of the invention to provide novel pharmaceuticalcompositions useful for treating dyslipidemia, which pharmaceuticalcompositions are more effective in treating the disease. It is anotherobject of the invention to provide novel pharmaceutical compositionsuseful for treating dyslipidemia, which pharmaceutical compositionscomprise a phosphopantetheine compound. It is another object of theinvention to provide novel pharmaceutical compositions useful fortreating dyslipidemia, which pharmaceutical compositions have less sideeffects, e.g., show decreased toxicity, when treating the disease. It isfurther an object of the invention to provide novel pharmaceuticalcompositions useful for treating dyslipidemia, which pharmaceuticalcompositions comprise compounds which are more stable in human serum.The present invention also relates to treatment methods usingpharmaceutical compositions of the invention, and to medicaments usefulin treating dyslipidemia.

One aspect of the invention relates to a compound having a structuralformula:

-   -   wherein:    -   Ra is H,

-   -    preferably

-   -   and; wherein:    -   R₁ is —H, unsubstituted or substituted alkyl, unsubstituted or        substituted alkenyl, substituted or unsubstituted cycloalkyl,        substituted or unsubstituted aryl, substituted or unsubstituted        arylalkyl, substituted or unsubstituted non-aromatic        heterocyclyl, substituted or unsubstituted aromatic        heterocyclyl, substituted or unsubstituted heterocyclylalkyl,        —COR₁₁, —C(O)OR₁₁, —C(O)NR₁₁R₁₂, —C═NR₁₁, —CN, —OR₁₁, —OC(O)R₁₁,        —NR₁₁R₁₂, —NR₁₁C(O)R₁₂, —NO₂, —N═CR₁₁R₁₂ or -halogen; preferably        C₁-C₁₀ alkyl, more preferably -methyl, -ethyl, -propyl or        -butyl, such as t-butyl, most preferred -methyl;    -   R₂, R₃, Rb and Rc are independently selected from the group        consisting of: —H, -methyl, -ethyl, -phenyl, acetoxymethyl (AM),        pivaloyloxymethyl (POM),

-   -    or    -   R₂ and R₃ or Rb and Rc jointly form a structure selected from        the group consisting of:

-   -    wherein    -   R₄ is —H or -alkyl, preferably -methyl;    -   R₅ is —H or -alkyl, preferably -methyl or t-butyl;    -   R₆ is —H, -alkyl, or —CH₂(CO)OCH₃;    -   R₇ is —H, -alkyl or -halogen;    -   R₈ is —H, -alkyl, preferably t-butyl;    -   R₉ is —H, -alkyl, preferably -methyl or t-butyl;    -   R₁₀ is —H, -alkyl, preferably -methyl or t-butyl;    -   R₁₁ and R₁₂ are each independently selected from hydrogen,        substituted or unsubstituted alkyl, substituted or unsubstituted        cycloalkyl, substituted or unsubstituted alkenyl, substituted or        unsubstituted aryl, substituted or unsubstituted heterocyclyl,        substituted or unsubstituted alkoxy, substituted or        unsubstituted aryloxy, or halogen;        or a pharmaceutically acceptable salt or solvate thereof        for use in the treatment or prevention of dyslipidemia,        hyperlipidemia, elevated blood cholesterol, elevated blood        triglicerides, combined hyperlipidemia, artherosclerosis,        cardiovascular disease, heart attack or stroke; preferably        elevated blood cholesterol, elevated blood triglicerides,        combined hyperlipidemia, artherosclerosis or cardiovascular        disease; more preferably elevated blood cholesterol, elevated        blood triglicerides or combined hyperlipidemia. In particularly        preferred embodiments, said compound is useful for treating or        preventing combined hyperlipidemia.

Preferred alkyl groups in the above definitions are -methyl, -ethyl,-propyl, -butyl, preferably t-butyl.

The D stereoisomeric configuration of carbon atoms marked with “*” isgenerally preferred.

In structures of the invention, a straight line overlayed by a wavy linedenotes the covalent bond of the respective residue to the Structure I.

In preferred embodiments, R_(a), R₂ and R₃ are H(4′-phosphopantetheine).

In preferred embodiments, R2, R3, Rb and Rc are identical residues. —H,bis-POM and bis-AM structures are particularly preferred.

In particularly preferred embodiments of any aspect of the invention,R₂, R₃, Rb and Rc are all ethyl or all -phenyl. In other preferredembodiments, R₂ and Rb are -ethyl and R₃ and Rc are -phenyl, or R₃ andRc are -ethyl and R₂ and Rb are -phenyl.

In a second preferred embodiment, R₂, R₃, Rb and Rc are all

where R₄ is —H, methyl; R₅ is alkyl, such as methyl or t-butyl.Preferably R₄ is —H and R₅ is -methyl. Hence, R₂, R₃, Rb and Rc may allbe acetoxymethyl (AM). In another embodiment R₄ is —H and R₅ is t-butyl.Hence, R₂, R₃, Rb and Rc may all be pivaloyloxymethyl (POM).

In a third preferred embodiment, R₂ and R₃ are both

In a fourth preferred embodiment, R₂, R₃, Rb and Rc are all

wherein R₆ is —H, -alkyl or —CH₂(CO)OCH₃.

In a fifth preferred embodiment, the phosphate group forms a cyclicphosphate according to the following structure:

wherein R₇ is alkyl or halogen or the cyclic phosphate includes:

wherein R₈ is t-butyl.

In a sixth preferred embodiment, R₂ and R₃ are bothS-[(2-hydroxyethyl)sulfidyl]-2-thioethyl (DTE), or

wherein R₉ is alkyl, preferably -methyl, -ethyl, -propyl or -butyl, suchas t-butyl.

In a seventh preferred embodiment, R₂, R₃, Rb and Rc are allS-acyl-2-thioethyl (SATE), or

wherein R₁₀ is alkyl, preferably -methyl, -ethyl, -propyl or -butyl,such as t-butyl.

In another embodiment, the present invention relates to pharmaceuticalcompositions comprising an HMG-CoA reductase inhibitor and aphosphopantetheine compound or a pharmaceutically acceptable salt orsolvate thereof and use of said pharmaceutical compositions for thetreatment of dyslipdemia, such as hyperlipidemia and combinedhyperlipidemia.

The present invention thus relates to a pharmaceutical compositioncomprising an HMG-CoA reductase inhibitor and a phosphopantetheinecompound or a pharmaceutically acceptable salt or solvate thereof.

In preferred embodiments the HMG-CoA reductase inhibitor in thepharmaceutical composition according to this invention is selected fromthe group consisting of lovastatin, simvastatin, pravastatin,fluvastatin, atorvastatin, cerivastatin, mevastatin, rosuvastatin,preferably atorvastatin and rosuvastatin, more preferably atorvastatin.

Therefore, in one aspect this invention relates to pharmaceuticalcomposition comprising an HMG-CoA reductase inhibitor and aphosphopantetheine compound wherein said phosphopantetheine compoundcorresponds to the chemical formula

-   -   wherein:    -   Ra is H,

-   -    preferably

-   -   and; wherein:    -   R₁ is —H, unsubstituted or substituted alkyl, unsubstituted or        substituted alkenyl, substituted or unsubstituted cycloalkyl,        substituted or unsubstituted aryl, substituted or unsubstituted        arylalkyl, substituted or unsubstituted non-aromatic        heterocyclyl, substituted or unsubstituted aromatic        heterocyclyl, substituted or unsubstituted heterocyclylalkyl,        —COR₁₁, —C(O)OR₁₁, —C(O)NR₁₁R₁₂, —C═NR₁₁, —CN, —OR₁₁, —OC(O)R₁₁,        —NR₁₁R₁₂, —NR₁₁C(O)R₁₂, —NO₂, —N═CR₁₁R₁₂ or -halogen; preferably        C₁-C₁₀ alkyl, more preferably -methyl, -ethyl, -propyl or        -butyl, such as t-butyl, most preferred -methyl;    -   R₂, R₃, Rb and Rc are independently selected from the group        consisting of: —H, -methyl, -ethyl, -phenyl, acetoxymethyl (AM),        pivaloyloxymethyl (POM),

-   -    or    -   R₂ and R₃ or Rb and Rc jointly form a structure selected from        the group consisting of:

-   -    wherein    -   R₄ is —H or -alkyl, preferably -methyl;    -   R₅ is —H or -alkyl, preferably -methyl or t-butyl;    -   R₆ is —H, -alkyl, or —CH₂(CO)OCH₃;    -   R₇ is —H, -alkyl or -halogen;    -   R₈ is —H, -alkyl, preferably t-butyl;    -   R₉ is —H, -alkyl, preferably -methyl or t-butyl;    -   R₁₀ is —H, -alkyl, preferably -methyl or t-butyl;    -   R₁₁ and R₁₂ are each independently selected from hydrogen,        substituted or unsubstituted alkyl, substituted or unsubstituted        cycloalkyl, substituted or unsubstituted alkenyl, substituted or        unsubstituted aryl, substituted or unsubstituted heterocyclyl,        substituted or unsubstituted alkoxy, substituted or        unsubstituted aryloxy, or halogen;        or a pharmaceutically acceptable salt or solvate thereof.

Preferred alkyl groups in the above definitions are -methyl, -ethyl,-propyl, -butyl, preferably t-butyl.

The D stereoisomeric configuration of carbon atoms marked with “*” isgenerally preferred.

In structures of the invention, a straight line overlayed by a wavy linedenotes the covalent bond of the respective residue to the Structure I.

In preferred embodiments, R2, R3, Rb and Rc are identical residues. —H,bis-POM and bis-AM structures are particularly preferred.

In particularly preferred embodiments of any aspect of the invention,R₂, R₃, Rb and Rc are all ethyl or all -phenyl. In other preferredembodiments, R₂ and Rb are -ethyl and R₃ and Rc are -phenyl, or R₃ andRc are -ethyl and R₂ and Rb are -phenyl.

In a second preferred embodiment, R₂, R₃, Rb and Rc are all

where R₄ is —H, methyl; R₅ is alkyl, such as methyl or t-butyl.Preferably R₄ is —H and R₅ is -methyl. Hence, R₂, R₃, Rb and Rc may allbe acetoxymethyl (AM). In another embodiment R₄ is —H and R₅ is t-butyl.Hence, R₂, R₃, Rb and Rc may all be pivaloyloxymethyl (POM).

In a third preferred embodiment, R₂ and R₃ are both

In a fourth preferred embodiment, R2, R3, Rb and Rc are all

wherein R₆ is —H, -alkyl or —CH₂(CO)OCH₃.

In a fifth preferred embodiment, the phosphate group forms a cyclicphosphate according to the following structure:

wherein R₇ is alkyl or halogen or the cyclic phosphate includes:

wherein R₈ is t-butyl.

In a sixth embodiment, R₂ and R₃ are bothS-[(2-hydroxyethyl)sulfidyl]-2-thioethyl (DTE), or

wherein R₉ is alkyl, preferably -methyl, -ethyl, -propyl or -butyl, suchas t-butyl.

In a seventh preferred embodiment, R₂, R₃, Rb and Rc are allS-acyl-2-thioethyl (SATE), or

wherein R₁₀ is alkyl, preferably -methyl, -ethyl, -propyl or -butyl,such as t-butyl.

Preferred alkyl groups are -methyl, -ethyl, -propyl, -butyl, preferablyt-butyl.

The D stereoisomeric configuration of carbon atoms marked with “*” isgenerally preferred.

In preferred embodiments, said pharmaceutical composition is useful inthe treatment or prevention of dyslipidemia, hyperlipidemia, elevatedblood cholesterol, elevated blood triglicerides, combinedhyperlipidemia, artherosclerosis, cardiovascular disease, heart attackor stroke; preferably elevated blood cholesterol, elevated bloodtriglicerides, combined hyperlipidemia, artherosclerosis orcardiovascular disease; more preferably elevated blood cholesterol,elevated blood triglicerides or combined hyperlipidemia. In particularlypreferred embodiments, said pharmaceutical composition is useful in thetreatment or prevention combined hyperlipidemia.

Hence, an aspect of the invention relates to a method for treating orpreventing of dyslipidemia, hyperlipidemia, elevated blood cholesterol,elevated blood triglicerides, combined hyperlipidemia, artherosclerosis,cardiovascular disease, heart attack or stroke. Even more preferably thepresent invention relates to a method for the treatment or prevention ofelevated blood cholesterol, elevated blood triglicerides, combinedhyperlipidemia, artherosclerosis or cardiovascular disease. In morepreferred embodiments the present invention relates to a method for thetreatment or prevention of elevated blood cholesterol, elevated bloodtriglicerides or combined hyperlipidemia. In most preferred embodimentsthe present invention relates to a method for the treatment orprevention of combined hyperlipidemia.

In further embodiments, the present invention relates to the use of saidpharmaceutical composition for treating or preventing elevated bloodcholesterol in a mammal in need thereof comprising administering anHMG-CoA reductase inhibitor and a phosphopantetheine compound.Preferably, said mammal is a human.

In further embodiments, the present invention relates the use of saidpharmaceutical composition for treating or preventing elevated bloodcholesterol in a mammal in need thereof comprising sequentiallyadministering a phosphopantetheine compound and an HMG-CoA reductaseinhibitor. Preferably, said mammal is a human.

In further embodiments, the present invention relates the use of saidpharmaceutical composition for treating or preventing artherosclerosisin a mammal in need thereof comprising administering aphosphopantetheine compound and an HMG-CoA reductase inhibitor.Preferably, said mammal is a human.

In further embodiments, the present invention relates the use of saidpharmaceutical composition for treating or preventing cardiovasculardisease in a mammal in need thereof comprising administering aphosphopantetheine compound and an HMG-CoA reductase inhibitor.Preferably, said mammal is a human.

In further embodiments, the present invention relates the use of saidpharmaceutical composition for treating or preventing heart attack in amammal in need thereof comprising administering a phosphopantetheinecompound and an HMG-CoA reductase inhibitor. Preferably, said mammal isa human.

In further embodiments, the present invention relates the use of saidpharmaceutical composition for treating or preventing stroke in a mammalin need thereof comprising administering a phosphopantetheine compoundand an HMG-CoA reductase inhibitor. Preferably, said mammal is a human.

In further embodiments, the present invention relates the use of saidpharmaceutical composition for treating or preventing combinedhyperlipidemia in a mammal in need thereof comprising administering aphosphopantetheine compound and an HMG-CoA reductase inhibitor.Preferably, said mammal is a human.

In further embodiments, the present invention relates to the use of acomposition in the manufacture of a medicament for treating orpreventing elevated blood cholesterol in a mammal in need thereof, saidcomposition comprising an HMG-Co A reductase inhibitor and aphosphopantetheine compound.

In yet another embodiment the present invention relates to a kitcomprising in separate containers in a single package pharmaceuticalcompositions for use in combination which comprises in one container apharmaceutical composition comprising an effective amount of a HMG-CoAreductase inhibitor in a pharmaceutically acceptable carrier, and in asecond-container, a pharmaceutical composition comprising an effectiveamount of a phosphopantetheine compound.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 shows the conversion of CoA into stable 4′-phosphopantetheine(4PPT) upon incubation of CoA in human serum. The graph shows relativelevels determined by HPLC analysis of CoA and 4PPT in human serum over 6hours incubation. It demonstrates that CoA is degraded in human serumand converted into stable 4PPT.

FIG. 2 shows the rescue potential of external supplementation of CoA or4′-phosphopantetheine of a CoA-deprived phenotype in HoPan-(calcium4-[[(2R)-2,4-dihydroxy-3,3-dimethylbutanoyl]amino]butanoate))-inducedreduction of cell count in mammalian HEK293 cells. This novel resultshows that 4PPT is as potent as CoA, this is because CoA is convertedinto 4PPT in serum

FIG. 3 shows the rescue potential of external supplementation of CoA or4′-phosphopantetheine of a CoA-deprived phenotype in HoPan-(calcium4-[[(2R)-2,4-dihydroxy-3,3-dimethylbutanoyl]amino]butanoate))-inducedintracellular reduction of CoA levels in mammalian HEK293 cells. Thisnovel result shows that 4PPT is as potent as CoA, this is because CoA isconverted into 4PPT in serum.

DETAILED DESCRIPTION OF THE INVENTION

Within the context of the present invention the term “combinedhyperlipidemia” refers to concurrent occurrence of hypercholesterolemiaand hypertriglyceridemia.

The term “alkyl” refers to a straight or branched hydrocarbon chainradical consisting of carbon and hydrogen atoms, containing nosaturation, having one to eight carbon atoms, and which is attached tothe rest of the molecule by a single bond, e.g., methyl, ethyl,n-propyl, i-propyl, n-butyl, t-butyl, n-pentyl, etc. Alkyl radicals maybe optionally substituted by one or more substituents such as a aryl,halo, hydroxy, alkoxy, carboxy, cyano, carbonyl, acyl, alkoxycarbonyl,amino, nitro, mercapto, alkylthio, etc. If substituted by aryl we havean “Aralkyl” radical, such as benzyl and phenethyl.

“Alkenyl” refers to an alkyl radical having at least two carbon atomscovalently connected by a double bond.

“Cycloalkyl” refers to a stable 3- to 10-membered monocyclic or bicyclicradical which is saturated or partially saturated, and which consistsolely of carbon and hydrogen atoms, such as cyclohexyl or adamantyl.Unless otherwise defined, the term“cycloalkyl” is meant to includecycloalkyl radicals which are optionally substituted by one or moresubstituents such as alkyl, halo, hydroxy, amino, cyano, nitro, alkoxy,carboxy, alkoxycarbonyl.

“Aryl” refers to single and multiple ring radicals, including multiplering radicals that contain separate and/or fused aryl groups. Typicalaryl groups contain from 1 to 3 separated or fused rings and from 6 toabout 18 carbon ring atoms, such as phenyl, naphthyl, indenyl,fenanthryl or anthracyl radical. The aryl radical may be optionallysubstituted by one or more substituents such as hydroxy, mercapto, halo,alkyl, phenyl, alkoxy, haloalkyl, nitro, cyano, dialkylamino,aminoalkyl, acyl, alkoxycarbonyl, etc.

“Heterocyclyl” refers to a stable 3-to 15 membered ring radical whichconsists of carbon atoms and from one to five heteroatoms selected fromthe group consisting of nitrogen, oxygen, and sulfur, preferably a 4-to8-membered ring with one or more heteroatoms, more preferably a 5- or6-membered ring with one or more heteroatoms. It may be aromatic or not.For the purposes of this invention, the heterocycle may be a monocyclic,bicyclic or tricyclic ring system, which may include fused ring systems;and the nitrogen, carbon or sulfur atoms in the heterocyclyl radical maybe optionally oxidised; the nitrogen atom may be optionally quaternized;and the heterocyclyl radical may be partially or fully saturated oraromatic. Examples of such heterocycles include, but are not limited to,azepines, benzimidazole, benzothiazole, furan, isothiazole, imidazole,indole, piperidine, piperazine, purine, quinoline, thiadiazole,tetrahydrofuran, coumarine, morpholine; pyrrole, pyrazole, oxazole,isoxazole, triazole, imidazole, etc.

“Alkoxy” refers to a radical of the formula —ORa where Ra is an alkylradical as defined above, e. g., methoxy, ethoxy, propoxy, etc.

References herein to “substituted” groups in the compounds of thepresent invention refer to the specified moiety that is substituted atone or more available positions by one or more suitable groups, e. g.,halogen such as fluoro, chloro, bromo and iodo, cyano, hydroxyl, nitro,azido, alkanoyl such as a C1-6 alkanoyl group such as acyl and the like,carboxamido, alkyl groups including those groups having 1 to about 12carbon atoms or from 1 to about 6 carbon atoms and more preferably 1-3carbon atoms, alkenyl and alkynyl groups including groups having one ormore unsaturated linkages and from 2 to about 12 carbon or from 2 toabout 6 carbon atoms, alkoxy groups having one or more oxygen linkagesand from 1 to about 12 carbon atoms or 1 to about 6 carbon atoms,aryloxy such as phenoxy, alkylthio groups including those moietieshaving one or more thioether linkages and from 1 to about 12 carbonatoms or from 1 to about 6 carbon atoms, alkylsulfinyl groups includingthose moieties having one or more sulfinyl linkages and from 1 to about12 carbon atoms or from 1 to about 6 carbon atoms, alkylsulfonyl groupsincluding those moieties having one or more sulfonyl linkages and from 1to about 12 carbon atoms or from 1 to about 6 carbon atoms, aminoalkylgroups such as groups having one or more N atoms and from 1 to about 12carbon atoms or from 1 to about 6 carbon atoms; carbocylic aryl having 6or more carbons, particularly phenyl or naphthyl and aralkyl such asbenzyl. Unless otherwise indicated, an optionally substituted group mayhave a substituent at each substitutable position of the group, and eachsubstitution is independent of the other.

The term “pharmaceutically acceptable salts or solvates” refers to anypharmaceutically acceptable salt, solvate, or any other compound which,upon administration to the recipient is capable of providing (directlyor indirectly) a compound as described herein. However, it will beappreciated that non-pharmaceutically acceptable salts also fall withinthe scope of the invention since those may be useful in the preparationof pharmaceutically acceptable salts. The preparation of salts, prodrugsand derivatives can be carried out by methods known in the art. Forinstance, pharmaceutically acceptable salts of compounds provided hereinare synthesized from the parent compound which contains a basic oracidic moiety by conventional chemical methods. Generally, such saltsare, for example, prepared by reacting the free acid or base forms ofthese compounds with a stoichiometric amount of the appropriate base oracid in water or in an organic solvent or in a mixture of the two.Generally, nonaqueous media like ether, ethyl acetate, ethanol,isopropanol or acetonitrile are preferred. Examples of the acid additionsalts include mineral acid addition salts such as, for example,hydrochloride, hydrobromide, hydroiodide, sulphate, nitrate, phosphate,and organic acid addition salts such as, for example, acetate, maleate,fumarate, citrate, oxalate, succinate, tartrate, malate, mandelate,methanesulphonate and p-toluenesulphonate. Examples of the alkaliaddition salts include inorganic salts such as, for example, sodium,potassium, calcium, ammonium, magnesium, aluminium and lithium salts,and organic alkali salts such as, for example, ethylenediamine,ethanolamine, N,N-dialkylenethanolamine, triethanolamine, glucamine andbasic aminoacids salts.

The term “phosphopantetheine compound” refers to the chemical formula

-   -   wherein:    -   Ra is H,

-   -    preferably

-   -   and; wherein:    -   R₁ is —H, unsubstituted or substituted alkyl, unsubstituted or        substituted alkenyl, substituted or unsubstituted cycloalkyl,        substituted or unsubstituted aryl, substituted or unsubstituted        arylalkyl, substituted or unsubstituted non-aromatic        heterocyclyl, substituted or unsubstituted aromatic        heterocyclyl, substituted or unsubstituted heterocyclylalkyl,        —COR₁₁, —C(O)OR₁₁, —C(O)NR₁₁R₁₂, —C═NR₁₁, —CN, —OR₁₁, —OC(O)R₁₁,        —NR₁₁R₁₂, —NR₁₁C(O)R₁₂, —NO₂, —N═CR₁₁R₁₂ or -halogen; preferably        C₁-C₁₀ alkyl, more preferably -methyl, -ethyl, -propyl or        -butyl, such as t-butyl, most preferred -methyl;    -   R₂, R₃, Rb and Rc are independently selected from the group        consisting of: —H, -methyl, -ethyl, -phenyl, acetoxymethyl (AM),        pivaloyloxymethyl (POM),

-   -    or    -   R₂ and R₃ or Rb and Rc jointly form a structure selected from        the group consisting of:

-   -    wherein    -   R₄ is —H or -alkyl, preferably -methyl;    -   R₅ is —H or -alkyl, preferably -methyl or t-butyl;    -   R₆ is —H, -alkyl, or —CH₂(CO)OCH₃;    -   R₇ is —H, -alkyl or -halogen;    -   R₈ is —H, -alkyl, preferably t-butyl;    -   R₉ is —H, -alkyl, preferably -methyl or t-butyl;    -   R₁₀ is —H, -alkyl, preferably -methyl or t-butyl;    -   R₁₁ and R₁₂ are each independently selected from hydrogen,        substituted or unsubstituted alkyl, substituted or unsubstituted        cycloalkyl, substituted or unsubstituted alkenyl, substituted or        unsubstituted aryl, substituted or unsubstituted heterocyclyl,        substituted or unsubstituted alkoxy, substituted or        unsubstituted aryloxy, or halogen.

Preferred alkyl groups in the above definitions are -methyl, -ethyl,-propyl, -butyl, preferably t-butyl.

The D stereoisomeric configuration of carbon atoms marked with “*” isgenerally preferred.

In structures of the invention, a straight line overlayed by a wavy linedenotes the covalent bond of the respective residue to the Structure I.

In preferred embodiments, R_(a), R₂ and R₃ are H(4′-phosphopantetheine).

In preferred embodiments, R2, R3, Rb and Rc are identical residues. —H,bis-POM and bis-AM structures are particularly preferred. Inparticularly preferred embodiments of any aspect of the invention, R₂,R₃, Rb and Rc are all ethyl or all -phenyl. In other preferredembodiments, R₂ and Rb are -ethyl and R₃ and Rc are -phenyl, or R₃ andRc are -ethyl and R₂ and Rb are -phenyl.

In a second preferred embodiment, R₂, R₃, Rb and Rc are all

where R₄ is —H, methyl; R₅ is alkyl, such as methyl or t-butyl.Preferably R₄ is —H and R₅ is -methyl. Hence, R₂, R₃, Rb and Rc may allbe acetoxymethyl (AM). In another embodiment R₄ is —H and R₅ is t-butyl.Hence, R₂, R₃, Rb and Rc may all be pivaloyloxymethyl (POM).

In third preferred embodiment, R₂ and R₃ are both

In a fourth preferred embodiment, R₂, R₃, Rb and Rc are all

wherein R₆ is —H, -alkyl or —CH₂(CO)OCH₃.

In fifth preferred embodiment, the phosphate group forms a cyclicphosphate according to the following structure:

wherein R₇ is alkyl or halogen or the cyclic phosphate includes:

wherein R₈ is t-butyl.

In sixth preferred embodiment, R₂ and R₃ are bothS-[(2-hydroxyethyl)sulfidyl]-2-thioethyl (DTE), or

wherein R₉ is alkyl, preferably -methyl, -ethyl, -propyl or -butyl, suchas t-butyl.

In a seventh preferred embodiment, R₂, R₃, Rb and Rc are allS-acyl-2-thioethyl (SATE), or

wherein R₁₀ is alkyl, preferably -methyl, -ethyl, -propyl or -butyl,such as t-butyl.

Pharmaceutical composition comprising a phosphopantetheine compound or acombination comprising an HMG-CoA reductase inhibitor and aphosphopantetheine compound is particularly suitable for treatment orprevention of hypercholesterolemia and hypertriglyceridemia which isherein referred to as “combined hyperlipidemia”.

This invention is based on our new and surprising finding that inmammalian serum Coenzyme A is rapidly hydrolyzed, likely byecto-nucleotide-pyrophosphatases to 4′-phosphopantetheine. Moreover wedetermined that 4′-phosphopantetheine is a biologically stable moleculethat surprisingly is able to effectively translocate through cellmembranes in spite of the charge present on the phosphate group. Insidethe cell, 4′-phosphopantetheine is enzymatically converted to Coenzyme Aby the bi-functional enzyme CoA synthase.

Up to now, the de novo biosynthetic pathway starting with the uptake ofvitamin B5 was the only known route for cells and organisms to obtainCoA. This invention is based on our finding that extracellular sourcesof CoA influence intracellular CoA levels both in vitro and in vivo. Ourresults also show that CoA is not a biologically stable molecule andthat cells do not absorb CoA directly. Surprisingly in fact, CoA in theserum is hydrolized into a stable product 4′-phosphopantetheine byecto-nucleotide-pyrophosphatases. 4′-phosphopantetheine can then betaken up by cells and converted to CoA. Via this route, exogenous CoArescues CoA-deprived phenotypes at the cellular, developmental,organismal and behavioral level. We prove that CoA-deprived phenotypescan also be rescued by 4′-phosphopantetheine, an intermediate in CoAbiosynthetic pathway. This proves that CoA rescue is independent of thefirst three classic CoA biosynthetic steps (PANK, PPCS and PPCDC) andthat it depends only on the last bifunctional enzyme COASY. Our datatherefore demonstrate the existence of an previously unsuspectedalternate mechanism for cells and organisms to influence intracellularCoA levels derived from an extracellular CoA source with4′-phosphopantetheine as the key intermediate and hereby surprisinglydemonstrating the high potential of 4′-phosphopantetheine.

Our findings have direct implications for the treatment or prevention ofdyslipidemia, hyperlipidemia, elevated blood cholesterol, elevated bloodtriglicerides, combined hyperlipidemia, artherosclerosis, cardiovasculardisease, heart attack or stroke. Patients suffering from hyperlipidemiawere recently shown to benefit from a combined treatment of statins and400 U Coenzyme A/day for 3 weeks [Lai et al. Lipids in Health andDisease, 2014, 13:1]. This combination was more effective compared tostatins alone, demonstrating two things: CoA has an effect when orallyprovided; and no toxicity was observed following 3 weeks ofadministration. Based on our unsuspected findings that CoA is rapidlydegraded to 4′-phosphopatetheine, these clinical data also imply atolerance and efficacy for 4′-phosphopatetheine.

From the point of view of drug development we realized that4′-phosphopantetheine has several important advantages compared to CoA.On one hand 4′-phosphopantetheine can be obtained by much simplerchemical synthesis procedure mastered by us and described in the patentapplication PCT/EP2014/073258 (published as WO2015/063177) which isherein incorporated in its entirety. More importantly, in contrast tochemically extremely complex CoA, derivatives of 4′-phosphopantetheinecan be readily obtained resulting in compounds with advantageouspharmacological properties, as also described in PCT/EP2014/073258.Furthermore, 4′phosphopantetheine is a serum-stable compound in contrastto CoA. Also, 4′-phosphopantetheine is able to translocate through cellmembranes in contrast to CoA.

Thus for treatment of dyslipidemia, hyperlipidemia, elevated bloodcholesterol, elevated blood triglicerides, combined hyperlipidemia,artherosclerosis, cardiovascular disease, heart attack or stroke apharmaceutical composition comprising a combination of a HMG-CoAreductase inhibitor and phosphopantetheine compound is clearly superiorto the combination of HMG-CoA reductase inhibitor and CoA which wasshown effective and safe before [Lai et al. Lipids in Health andDisease, 2014, 13:1]. Based on our results we claim in addition thatphosphopantetheine compounds alone will be effective as treatment ofdyslipidemia, hyperlipidemia, elevated blood cholesterol, elevated bloodtriglicerides, combined hyperlipidemia, artherosclerosis, cardiovasculardisease, heart attack or stroke.

EXAMPLES Example 1. Conversion of CoA into 4′-phosphopantetheine inHuman Serum

Materials and Methods: CoA (purchased from Sigma) was incubated at afinal concentration of 10 μM human serum for 6 hours at 37° C. Afterincubation, the samples were processed to remove proteins and HPLCanalysis was used to assess the amount of remaining compound CoA andamount of generated 4′-phosphopantetheine, indicating conversion of CoAto 4′-phosphopantetheine.

Results: CoA is significantly degraded (60%). already in 3 initial hoursof incubation, most likely by ecto-nucleotide-pyrophosphatases. Inparallel with CoA degradation the concentrations of4′-phosphopantetheine were observed to increase confirming that CoA isconverted into 4′-phosphopantetheine (FIG. 1).

Example 2: Rescue Potential of CoA and 4′-phosphopantetheine in HOPANAssay

Mammalian HEK293 cells treated with the chemical inhibitor HOPAN(hopanthenate, CAS 17097-76-6, IUPAC: calcium4-[[(2R)-2,4-dihydroxy-3,3-dimethylbutanoyl]amino]butanoate). Cellstreated with HOPAN show a reduction in intracellular CoA levels, whichinduces a decrease in cell viability. Herewith, the result is includedto demonstrate the rescue efficiency of CoA as well as4′-phosphopantetheine in such model system.

Materials and Methods: HEK293 cells were cultured in vitamin B5deficient DMEM (Thermo Scientific) supplemented with 10% dialysed FCS(Thermo Scientific) with and without HOPAN (0.5 mM) and CoA and4′-phosphopantetheine for 4 days. 250 μM of CoA and4′-phosphopantetheine was used for determination of rescue efficiency.

Result: The result indicates that CoA and 4′-phosphopantetheinesignificantly rescued the HOPAN (0.5 mM) induced decrease ofintracellular CoA levels (FIG. 3) and rescued the cell count defect(FIG. 2).

Example 3. Film Coated Tablets

The film-coated tablet is manufactured e.g. as follows:

A mixture of calcium salt of 4′-phosphopantetheine, calcium salt ofatorvastatin, microcrystalline cellulose, crospovidone, part of thecolloidal anhydrous silica/colloidal silicon dioxide/Aerosile 200,silicon dioxide and magnesium stearate is premixed in a diffusion mixerand then sieve through a screening mill. The resulting mixture is againpremixed in a diffusion mixer, compacted in a roller compacter and thensieved through a screening mill. To the resulting mixture, the rest ofthe colloidal anhydrous silica/colloidal silicon dioxide/Aerosile 200are added and the final blend is made in a diffusion mixer. The wholemixture is compressed in a rotary tabletting machine and the tablets arecoated with a film by using Diolack pale red in a perforated pan.

Composition per unit Component [mg] Standards 4′-phosphopantetheine,calcium salt 300 Atorvastatin, calcium salt trihydrate 21.7 Ph. EurMicrocristaline cellulose/Avicel PH 102 212 Ph. Eur Crospovidone 80 Ph.Eur Colloidal anhydrous silica/Colloidal silicon 3.2 Ph. Eurdioxide/Aerosil 200 Magnesium stearate 100 Ph. Eur Blending Colloidalanhydrous silica/Colloidal silicon 3.2 Ph. Eur dioxide/Aerosil 200Magnesium stearate 80 Ph. Eur Coating Purified water * / DIOLACK palered 00F34899 15 Total tablet mass 815.1 * Removed during processing

Example 4. Method for the Synthesis of 4′-phosphopantetheine(Corresponds to Example 9 of WO2015/063177)

D-Pantothenic acid was prepared from its hemicalcium salt (Aldrich,≥99.0%) reacting with oxalic acid. S-Tritylcysteamine was synthesizedfrom cysteamine hydrochloride and trityl chloride as reported by Mandelet al. [A. L. Mandel, et al., Org. Lett. 2004, 6, 26, 4801-4803].Dibenzylchlorophosphate was prepared by reacting dibenzylphosphite withN-chlorosuccinimide as described by Itoh et al. [K. Itoh et al., Org.Lett. 2007, 9, 5, 879-882] in toluene as a solvent. All other chemicalswere obtained from commercial sources and used without furtherpurification; cysteamine hydrochloride (Aldrich, ≥98.0%), tritylchloride (Aldrich, 97.0%),N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide (Aldrich, ≥97.0%),1-hydroxybenzotriazole hydrate (Aldrich, ≥97.0%), dibenzylphosphite(Aldrich, technical grade), N-chlorosuccinimide (Aldrich, 98%). Columnchromatography was carried out using Silica gel 60 Å, 60-100 mesh(Aldrich). Cation exchange chromatography was performed on DOWEX 50WX2,hydrogen form, 100-200 mesh (Aldrich). ¹H and ¹³C NMR were recorded at25° C. with Varian Unity Inova 300 MHz spectrometer (300 MHz/75 MHz).The chemical shifts (δ) are reported in ppm units relative to TMS as aninternal standard where spectra recorded in CDCl₃ or relative toresidual solvent signal when D₂O was used. High-resolution mass spectrawere obtained on AutospecQ mass spectrometer with negative electrosprayionization.

a) Coupling Reaction—Synthesis of S-tritylpantetheine

In dried acetonitrile (100 mL) were prepared separatly: (A)D-pantothenic acid (2.19 g, 10.0 mmol), (B) S-tritylcysteamine (3.19 g,10.0 mmol) and (C) N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide (1.55g, 10.0 mmol) together with 1-hydroxybenzotriazole hydrate (1.35 g, 10.0mmol). When mixed together (A), (B) and (C), triethylamine (10.4 mL, 75mmol) was added. The mixture was stirred at room temperature for 24 hand quenched with addition of water. The product was extracted withdiethyl ether. The combined organic phases were washed with 1 Mhydrochloric acid, saturated aqueous solution of NaHCO₃ and brine.Organic layer was dried over sodium sulfate and concentrated in vacuumto give S-tritylpantetheine (3.53 g, 68%) as pale-yellow crystals. ¹HNMR (300 MHz, CDCl₃) δ 0.85 (s, 3H), 0.92 (s, 3H), 2.29 (t, J=6.2 Hz,2H), 2.38 (t, J=6.4 Hz, 2H), 3.03 (dd, J=6.0, 5.2 Hz, 2H), 3.45 (m, 4H),3.92 (s, 1H), 6.20 (t, J=5.7 Hz, 1H, NH), 7.21 (m, 3H), 7.27 (m, 6H),7.39 (m, 6H).

b) Phosphorylation—Synthesis of S-trityl-4′-dibenzylphosphopantetheine

Dibenzylchlorophosphate was freshly prepared by reaction ofdibenzylphosphite (2.16 g, 8.24 mmol) with N-chlorosuccinimide (1.21 g,9.06 mmol) in toluene (40 mL) at room temperature for 2 h. The mixturewas filtered and the filtrate was evaporated under vacuum and added to asolution of S-tritylpantetheine (2.86 g, 5.49 mmol),diisopropylethylamine (3.06 mL), 4-dimethylaminopyridine (0.067 g, 0.55mmol) in dry acetonitrile. The mixture was stirred for 2 h at roomtemperature. Products were extracted into organic phase indichloromethane—aqueous NaHCO₃ system. The organic extracts were washedwith water and brine, and dried over Na₂SO₄. Evaporation of solvent gavea crude S-trityl-4′-dibenzylphosphopantetheine as a dark brown oil (4.69g), which was further purified by flash chromatography to give asemicrystaline pale yellow product (0.640 g, 0.82 mmol). The yield ofthe synthesis and purification of S-trityl-4′-dibenzylphosphopantetheineis 15%. ¹H NMR (300 MHz, CDCl₃) δ 0.75 (s, 3H), 1.03 (s, 3H), 2.32 (t,J=6.1 Hz, 2H), 2.4 (t, J=6.5 Hz, 2H), 3.06 (dd, J=6.5, 6.2 Hz, 2H), 3.47(dd, J=6.1, 6.0 Hz, 2H), 3.60 (dd, J=9.9, 7.3 Hz 1H), 3.85 (s, 1H), 4.00(dd, J=9.9, 7.0 Hz, 1H), 5.04 (m, 4H), 5.80 (t, J=5.5 Hz, 1H, NH),7.18-7.42 (m, 25H).

c) Deprotection—Synthesis of 4′-phosphopanetheine

Naphthalene (12.9 g, 100.6 mmol) dissolved in tetrahydrofuran (70 mL)was added to sodium metal (2.21 g, 96.1 mmol) in tetrahydrofuran (50mL). After 2 h the solution was cooled to −(35±5) ° C. andS-trityl-4′-dibenzylphosphopantetheine (1.85 g, 2.37 mmol) dissolved intetrahydrofuran (70 mL) was slowly added. The mixture was stirred for a2 h while maintaining the temperature below −30° C. The reaction wasquenched by addition of water and then dichloromethane was added.Aqueous phase was washed with dichloromethane and diethylether,concentrated under vacuum and passed through cation exchange column(DOWEX 50WX2). Fractions were analyzed by LCMS and those containing theproduct were pooled and concentrated under vacuum. 4′-phosphopanetheinewas precipitated with addition of Ca(OH)₂ as a calcium salt (332 mg,0.838 mmol, 35%). The structure of the product was confirmed bycomparison of NMR data with the literature [Lee, C—H. et al., J. Am.Chem. Soc. 1975, 1225-1236] and by HRMS. ¹H NMR (300 MHz, D₂O) δ 0.86(s, 3H), 1.08 (s, 3H), 2.54 (t, J=6.3 Hz, 2H), 2.87 (t, J=6.3 Hz, 2H),3.43 (dd, J=10.3, 5.0 Hz, 1H), 3.54 (m, 4H), 3.76 (dd, J=10.3, 6.5 Hz,1H), 4.14 (s, 1H). The HRMS mass for C₁₁H₂₂N₂O₇SP [M−H]⁻ was found to be357.0880, which corresponds to the expected mass of 357.0885.

Example 5. Method for Preparation of bis(pivaloyloxymethyl) ester ofS-acyl-4′-phosphopantetheine (Corresponds to Example 8 of WO2015/063177)

Preparation of Phosphorylating Reagent

Bis(POM) chloro phosphate for the phosphorylation ofS-acetil-pantetheine was prepared according to the published literature(Hwang Y et al., Organic Letters. 2004, 6, 1555; Ruda, G F et al.,ChemMedChem. 2007, 2, 1169).

Preparation of Tris(POM) Phosphate

To a solution of trimethyl phosphate (7.01 g, 50 mmol) in dry CH₃CN (42mL) were sequentially added chloromethylpivalate (29.35 g, 195 mmol) andNaI (22.52 g, 150 mmol). The reaction mixture was heated at reflux (80°C.) for 72 hours, cooled to ambient temperature and diluted with Et₂O(400 mL). The organic phase was washed with water (2×100 ml), saturatedNa₂S₂O₃ solution (2×100 mL), dried over Na₂SO₄ and concentrated.Purification on silica gel eluting with hexane/EtOAc 4:1 affordedviscous yellow oil (14.6 g, 66%): ¹H NMR (300 MHz, CDCl₃) δ 5.66 (d,J=13.7 Hz, 6H), 1.24 (s, 27H) ppm; ³¹P NMR (120 MHz, CDCl₃) δ −4.74 (s)ppm; HRMS (M+H⁺) calculated for C₁₈H₃₄O₁₀P 441.1890, found 441.1901.

Preparation of Bis(POM) Hydrogen Phosphate

Tris(POM) phosphate (1 g, 2.3 mmol) was dissolved in piperidine (7 mL)and stirred at room temperature for 12 h. The solution was concentratedand further evaporated in vacuo until constant weight. (935 mg, 99.0%yield). The crude oil (935 mg, 2.28 mmol) was dissolved in water (20 ml)and treated with Dowex W50X2 H form resin (19.2 g, 11.4 mmol, 0.6mmol/g). The suspension was stirred at ambient temperature for 1 hour.The resin was filtered and washed with water. The filtrate wasconcentrated and dried in vacuo affording a white solid (613 mg, 82%yield): ¹H NMR (300 MHz, CDCl₃) δ 8.45 (bs, 1H), 5.62 (d, J=13.2 Hz,4H), 1.23 (s, 18H) ppm; ³¹P NMR (120 MHz, CDCl₃) δ −3.17 (s) ppm.

Preparation of Bis(POM) Chloro Phosphate

A solution of bis(POM) hydrogen phosphate (613 mg, 1.88 mmol) and DMF(7.3 μL, 0.094 mmol) in DCM (7.5 mL) was added dropwise to a stirredsolution of oxalyl chloride (889 μL, 9.38 mmol) in DCM (7.5 mL) underargon at ambient temperature. Reaction mixture was stirred for 2 hours.The solvent was evaporated under argon to provide a crude yellow oil(671 mg, 1.86 mmol) which was directly used in the next step.

Preparation of S-acetil phosphopantetheine bis[(pivaloyloxy)methyl]ester

S-acetyl-pantetheine was prepared as described in [E. Walton et al., J.Am. Chem. Soc. 1954, 76, 1146]. To a stirred solution ofS-acetil-pantetheine (463 mg, 1.45 mmol), N,N-iisopropylethylamine (308μL, 1.77 mmol) and 4-Dimethylaminopyridine (10.9 mg, 0.09 mmol) in 10 mlof DCM at 0° C., was added dropwise under argon a solution of bis(POM)chloro phosphate (590 mg, 1.88 mmol) in 10 ml of DCM. Reaction mixturewas allowed to warm to room temperature and stirred for 12 hours. Thereaction was quenched with water (10 ml) and extracted with DCM (2×20ml). Organic phase was washed with saturated solution of NH₄Cl, driedover Na₂SO₄ and concentrated under reduced pressure. Purification onsilica gel eluting with DCM/MeOH, 92:8 afforded the product as a yellowoil (401 mg, 44% yield): ¹H NMR (300 MHz, CDCl₃) δ 7.25 (app t, J=6.2Hz, 1H), 6.39 (app t, J=5.3 Hz, 1H), 5.61-5.71 (m, 4H), 4.13 (dd,J=10.0, 6.9 Hz, 1H), 4.08 (d, J=6.3 Hz, 1H), 3.97 (d, J=5.8 Hz, 1H),3.75 (dd, J=10.0, 7.2 Hz, 1H), 3.51-3.63 (m, 2H), 3.34-3.50 (m, 2H),2.95-3.09 (m, 2H), 2.39-2.47 (m, 2H), 2.35 (s, 3H), 1.242 (s, 9H), 1.240(s, 9H), 1.12 (s, 3H), 0.88 (s, 3H) ppm; ³¹P NMR (120 MHz, CDCl₃) δ−2.64 (s) ppm.

The invention claimed is:
 1. A pharmaceutical composition comprising aphosphopantetheine compound or a pharmaceutically acceptable salt orsolvate thereof and an HMG-CoA reductase inhibitor, wherein thephosphopantetheine compound has the structural formula:

wherein: Ra is

R₁ is —H, unsubstituted or substituted alkyl, unsubstituted orsubstituted alkenyl, substituted or unsubstituted cycloalkyl,substituted or unsubstituted aryl, substituted or unsubstitutedarylalkyl, substituted or unsubstituted non-aromatic heterocyclyl,substituted or unsubstituted aromatic heterocyclyl, substituted orunsubstituted heterocyclylalkyl, —C═NR₁₁, —CN, —OR₁₁, —OC(O)R₁₁,—NR₁₁R₁₂, —NR₁₁C(O)R₁₂, —NO₂, —N═CR₁₁R₁₂ or -halogen; R₂ and R₃ areindependently selected from the group consisting of: —H, -methyl,-ethyl, -phenyl, acetoxymethyl (AM), pivaloyloxymethyl (POM),

 or R₂ and R₃ jointly form a structure selected from the groupconsisting of:

 wherein R₄ is —H or -alkyl; R₅ is —H or -alkyl; R₆ is —H, -alkyl, or—CH₂(CO)OCH₃; R₇ is —H, -alkyl, or -halogen; R₈ is —H or -alkyl; R₉ is—H or -alkyl; R₁₀ is —H or -alkyl; R₁₁ and R₁₂ are each independentlyselected from hydrogen, substituted or unsubstituted alkyl, substitutedor unsubstituted cycloalkyl, substituted or unsubstituted alkenyl,substituted or unsubstituted aryl, substituted or unsubstitutedheterocyclyl, substituted or unsubstituted alkoxy, substituted orunsubstituted aryloxy, and halogen.
 2. The composition of claim 1,wherein said HMG-CoA reductase inhibitor is selected from the groupconsisting of lovastatin, simvastatin, pravastatin, fluvastatin,atorvastatin, cerivastatin, mevastatin, rosuvastatin and thepharmaceutically acceptable lactones, open acids, salts, and estersthereof, and mixtures thereof.
 3. The composition of claim 1, wherein R₂and R₃ are identical residues.
 4. The composition of claim 1, wherein R₂and R₃ are each H.
 5. The composition of claim 1, wherein R₁ is methyl.6. The composition of claim 1, wherein R₁ is methyl, and R₂ and R₃ areeach H.
 7. The composition of claim 6, wherein the phosphopantetheinecompound is a D stereoisomer.
 8. The composition of claim 7, wherein thepharmaceutically acceptable salt or solvate of the phosphopantetheinecompound is a calcium salt.
 9. A kit comprising: a first pharmaceuticalcomposition comprising an effective amount of a HMG-CoA reductaseinhibitor, and a second pharmaceutical composition comprising aneffective amount of a phosphopantetheine compound or a pharmaceuticallyacceptable salt or solvate thereof, wherein the phosphopantetheinecompound has the chemical formula:

wherein: Ra is

wherein: R₁ is —H, unsubstituted or substituted alkyl, unsubstituted orsubstituted alkenyl, substituted or unsubstituted cycloalkyl,substituted or unsubstituted aryl, substituted or unsubstitutedarylalkyl, substituted or unsubstituted non-aromatic heterocyclyl,substituted or unsubstituted aromatic heterocyclyl, substituted orunsubstituted heterocyclylalkyl, —C═NR₁₁, —CN, —OR₁₁, —OC(O)R₁₁,—NR₁₁R₁₂, —NR₁₁C(O)R₁₂, —NO₂, —N═CR₁₁R₁₂ or -halogen; R₂ and R₃ areindependently selected from the group consisting of: —H, -methyl,-ethyl, -phenyl, acetoxymethyl (AM), pivaloyloxymethyl (POM),

 or R₂ and R₃ jointly form a structure selected from the groupconsisting of:

 wherein R₄ is —H or -alkyl; R₅ is —H or -alkyl; R₆ is —H, -alkyl, or—CH₂(CO)OCH₃; R₇ is —H, -alkyl, or -halogen; R₈ is —H or -alkyl; R₉ is—H or -alkyl; R₁₀ is —H or -alkyl; R₁₁ and R₁₂ are each independentlyselected from hydrogen, substituted or unsubstituted alkyl, substitutedor unsubstituted cycloalkyl, substituted or unsubstituted alkenyl,substituted or unsubstituted aryl, substituted or unsubstitutedheterocyclyl, substituted or unsubstituted alkoxy, substituted orunsubstituted aryloxy, and halogen.
 10. The kit of claim 9, wherein saidHMG-CoA reductase inhibitor is selected from the group consisting oflovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin,cerivastatin, mevastatin, rosuvastatin and the pharmaceuticallyacceptable lactones, open acids, salts, and esters thereof, and mixturesthereof.
 11. The kit of claim 9, wherein R₂ and R₃ are identicalresidues.
 12. The kit of claim 9, wherein R₂ and R₃ are each H.
 13. Thekit of claim 9, wherein R₁ is methyl.
 14. The kit of claim 9, wherein R₁is methyl, and R₂ and R₃ are each H.
 15. The kit of claim 14, whereinthe phosphopantetheine compound is a D stereoisomer.
 16. The kit ofclaim 15, wherein the pharmaceutically acceptable salt or solvate of thephosphopantetheine compound is a calcium salt.
 17. The composition ofclaim 1 for treating or preventing dyslipidemia, hyperlipidemia,elevated blood cholesterol, elevated blood triglycerides, combinedhyperlipidemia, artherosclerosis, cardiovascular disease, heart attack,or stroke.
 18. The kit of claim 9 for treating or preventingdyslipidemia, hyperlipidemia, elevated blood cholesterol, elevated bloodtriglycerides, combined hyperlipidemia, artherosclerosis, cardiovasculardisease, heart attack, or stroke.